Kestra Investment Management LLC Takes $27,000 Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Kestra Investment Management LLC purchased a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 307 shares of the medical equipment provider’s stock, valued at approximately $27,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in LNTH. CWM LLC lifted its position in shares of Lantheus by 63.0% during the 3rd quarter. CWM LLC now owns 750 shares of the medical equipment provider’s stock worth $82,000 after buying an additional 290 shares in the last quarter. Creative Planning lifted its holdings in Lantheus by 5.4% during the third quarter. Creative Planning now owns 24,988 shares of the medical equipment provider’s stock worth $2,742,000 after acquiring an additional 1,274 shares during the period. Signaturefd LLC lifted its holdings in Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 92 shares during the period. International Assets Investment Management LLC boosted its position in Lantheus by 4,324.9% in the third quarter. International Assets Investment Management LLC now owns 66,948 shares of the medical equipment provider’s stock worth $7,348,000 after purchasing an additional 65,435 shares during the last quarter. Finally, Assenagon Asset Management S.A. bought a new position in Lantheus in the 3rd quarter valued at $1,863,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Lantheus

In other news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the transaction, the director now directly owns 33,207 shares in the company, valued at approximately $3,146,695.32. The trade was a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.50% of the company’s stock.

Lantheus Stock Down 3.2 %

NASDAQ LNTH opened at $78.23 on Friday. The company’s 50 day moving average is $90.31 and its 200-day moving average is $97.05. The firm has a market cap of $5.44 billion, a P/E ratio of 13.02 and a beta of 0.44. Lantheus Holdings, Inc. has a 12-month low of $56.44 and a 12-month high of $126.89.

Analyst Ratings Changes

A number of equities research analysts have recently commented on LNTH shares. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. JMP Securities reissued a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a research report on Tuesday, January 14th. The Goldman Sachs Group assumed coverage on shares of Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 price target for the company. Finally, Truist Financial reiterated a “buy” rating and issued a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $131.86.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.